anastrozole / Generic mfg. - LARVOL DELTA

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database. (PubMed, Front Pharmacol) - "Sixty-one preferred terms (PTs) presented positive signals, including nail disorders, onychoclasis, and abnormal hair growth in patients on anastrozole, exemestane, or letrozole. Eleven dermatologic PTs had onset times under 50 days, with the earliest at 2 days; the latest, skin ulcer, appeared at 241.5 days with exemestane. The findings provide substantial evidence of dermatologic AEs associated with AIs, particularly anastrozole and exemestane, emphasizing the importance of dermatologic monitoring during AI therapy and the need for further research into AI-induced dermatologic AEs."

Adverse events • Journal • Dermatology

OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=510 | Recruiting | Sponsor: Olema Pharmaceuticals, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A Squeaky Lung Mass: A Case of a Rare NTM Disease (ATS 2025) - "We present the case of a 67-year-old female with a medical history of Hodgkin's disease treated with mantle radiation, breast cancer treated with bilateral mastectomy on anastrozole, and progressive lung disease with bronchiectasis status post-right middle and lower lobe lobectomies...Albuterol, N-acetylcysteine, as well as multiple courses of suppressive antibiotics with azithromycin and trimethoprim-sulfamethoxazole over several years provided some relief...The patient started on moxifloxacin, rifabutin, and ethambutol...Due to her history of bronchiectasis and lung resection, parenteral amikacin was considered. Once diagnosed, treatment courses are recommended to continue for at least 12 months from culture conversion. If culture conversion is not achieved, surgical intervention may be a consideration if tolerated, with an 87% culture conversion rate."

Clinical • Breast Cancer • Bronchiectasis • Hodgkin Lymphoma • Infectious Disease • Nontuberculous Mycobacterial Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Plasma Proteins Differ by Etiology and Six Minute Walk Distance in Patients With Pulmonary Arterial Hypertension (ATS 2025) - " PHANTOM was a phase II, randomized, double-blind, placebo-controlled clinical trial of 1 year of anastrozole (an aromatase inhibitor) versus placebo...This study identifies 15 plasma proteins associated with baseline 6MWD, 4 associated with change in 6MWD and 3 with PAH etiology. Several of these have demonstrated significance in PAH, including COL18A1, an angiostatic peptide previously shown to improve mortality risk prediction in PAH. Our work differentiates subsets of proteins associated with baseline 6MWD from those whose change over time corresponds to resulting change in 6MWD."

Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatology • COL18A1 • GDF15 • IGFBP7 • TNFSF13B

Breast Cancer to Lung Transplant: A Success Story (ATS 2025) - "She was treated with radiation and anastrozole...Her induction immunosuppression included basiliximab, methylprednisolone, and mycophenolate. Her post-op recovery was unremarkable except for delirium, which resolved after switching tacrolimus to cyclosporine. Her maintenance immunosuppression also includes mycophenolate and prednisone...Many of these patients with solid organ malignancies are turned down as transplant candidates due to risk of cancer recurrence given the need for immunosuppressive therapy. Advances in cancer treatment and personalized immunosuppression protocols suggest that life-saving transplants may be considered for select cancer survivors with multi-disciplinary team input."

Breast Cancer • CNS Disorders • Cough • HER2 Breast Cancer • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Solid Tumor • Transplantation • HER-2

Remote Monitoring of Physical Activity in Randomized Clinical Trial of Anastrozole in PAH - The PHANTOM Study (ATS 2025) - "Daily activity in PAH patients varies with both individual characteristics, such as age and functional status, and environmental factors like location and season. Greater activity levels were associated with better bone density, quality of life, and a lower risk of clinical worsening, in patients enrolled in this RCT. Future studies are needed to investigate these associations in a real-world population."

Clinical • Infectious Disease • Novel Coronavirus Disease • Obesity

Severe Biventricular Failure, ARDS, and DIC Linked to Fadogia Agrestis, Trimethylglycine, and Anastrozole: A Case Report on Unregulated Supplement and AAS Use (ATS 2025) - "This case highlights the potentially fatal consequences of unregulated testosterone and AAS use, leading to catastrophic cardiovascular and multi-system collapse. Clinicians should routinely screen for supplement use in patients with acute cardiac or respiratory distress. Urgent research is needed to better understand the toxicology of supplements like Fadogia agrestis, and stricter regulatory guidelines are warranted to prevent such fatal outcomes."

Case report • Clinical • Acute Respiratory Distress Syndrome • Cardiomyopathy • Cardiovascular • Dyslipidemia • Fibrosis • Hematological Disorders • Hypertension • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases • Thrombocytopenia

Initial Diagnosis of Metastatic Melanoma Confirmed on Endobronchial Ultrasound Biopsy (ATS 2025) - "She has a significant past medical history for left mastectomy for invasive ductal carcinoma that was triple positive and treated with anastrozole therapy five years prior...This patient did not have any delay in care or poor our come but the relainace on pre-existing medical conditions to guide diagnoses and common diagnoses can at times cloud our judgment. This case illustrates the value of a thorough diagnostic approach in ensuring accurate identification of conditions that may not initially align with a known medical history."

Biopsy • Endobronchial ultrasound • Metastases • Infectious Disease • Lung Cancer • Melanoma • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Development of Pulmonary Arteriovenous Malformations During Trastuzumab Emtansine Therapy for HER2-Positive Breast Cancer (ATS 2025) - "She underwent bilateral mastectomy and was treated with T-DM1 and anastrozole. The patient's condition improved after discontinuing T-DM1, suggesting a potential link between the drug and PAVMs. Understanding the mechanisms by which T-DM1 induces vascular abnormalities is crucial for developing targeted interventions and improving patient outcomes."

Anemia • Breast Cancer • CNS Disorders • Fatigue • Hematological Disorders • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Solid Tumor • ALK1 • HER-2

Cardiovascular risks associated with aromatase inhibitors versus tamoxifen in breast cancer: A systematic review and meta-analysis. (ASCO 2025) - "Background: Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used in the treatment of women with early or advanced-stage breast cancer (BC). This systematic review and meta-analysis indicate that AI treatment in BC patients is associated with an increased risk of heart failure, cardiomyopathy, and myocardial infarction. Notably, AI treatment demonstrated a protective effect against thromboembolic events."

Retrospective data • Review • Breast Cancer • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Ischemic stroke • Myocardial Infarction • Oncology • Solid Tumor

Clinical investigators' (CIs) practice patterns for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) harboring PI3K/AKT/PTEN pathway abnormalities (PAPm). (ASCO 2025) - "The recent availability of capi and inavo has significantly affected current practice patterns, with the majority of CIs rapidly incorporating these therapies into their treatment algorithms for specific patient types. Future work is needed to explore how other factors (eg, age, comorbidities, HER2-low status) and rapidly emerging clinical trial findings (eg, EMBER-3) affect decision-making. A = anastrozole; IPF = inavolisib + palbociclib + fulvestrant; F = fulvestrant; AI = aromatase inhibitor; C = capivasertib; Alp = alpelisib; E = elacestrant"

Clinical • Metastases • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA • PTEN

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice. (ASCO 2025) - P2 | " Pre- and perimenopausal women (N = 222) with no prior systemic therapy for clinically aggressive HR+/HER2− ABC were randomized 1:1 to receive RIB + letrozole or anastrozole + goserelin or physician's choice of combo CT. This analysis from RIGHT Choice showed similar clinically meaningful efficacy and quality-of-life benefits and no new safety signals for RIB + ET vs combo CT between pts with and without liver mets. These results support the 1L use of RIB + ET in pts with clinically aggressive HR+/HER2– ABC even in the presence of liver mets. NE, not evaluable."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors. (ASCO 2025) - P2, P3 | " OPERA-01 (NCT06016738) is a multicenter, randomized, open-label, phase 3 clinical trial comparing the efficacy and safety of palazestrant as a single agent to SOC ET (fulvestrant, anastrozole, letrozole, or exemestane) in patients with ER+, HER2– MBC that relapsed or progressed on 1-2 prior lines of ET, including a CDK4/6i. Secondary endpoints include overall survival, antitumor activity (objective response rate, clinical benefit rate, and duration of response), safety, exposure and patient-reported outcomes in patients with and without ESR1 mutations. Study recruitment began in November 2023."

Clinical • Metastases • Monotherapy • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study. (ASCO 2025) - P2 | "Eligible pts will be randomized 1:1:1 to alisertib 30 mg, 40 mg, or 50 mg orally twice daily on days 1−3, 8–10, and 15–17 every 28 days, plus physician's choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not previously used in recurrent/metastatic setting or progressed upon in adjuvant setting; ≤50 pts will be enrolled per arm in the USA and Europe. Tumor tissue will be centrally assessed for biomarkers, including RB1, MYC, TP53, ESR1, PI3K/AKT pathway, HER2 and AURKA genomic alterations/expression levels. The study will determine the optimal alisertib dose to combine with ET and may identify biomarker(s) defining pts with the greatest benefit from alisertib-based therapy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • ER • HER-2 • MYC • RB1

A process evaluation trial of a telehealth service intervention to support uptake of breast cancer prevention medications. (ASCO 2025) - "Funded by Tour de Cure Clinical Trial Registration Number: 15718519 Background: Breast cancer prevention medications (BCPrevMeds), such as tamoxifen and anastrozole, halve breast cancer (BC) risk. Currently 33 of a planned 63 participants have been recruited - sample size is based on 80% power to detect a change in uptake from 2% to 20%. Clinical Trial Information: ISRCTN 15718519"

Breast Cancer • Oncology • Solid Tumor

Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC). (ASCO 2025) - P3 | "Pts will receive RIB (400 mg/d; 3 wk on/1 wk off) + ET (letrozole 2.5 mg/d, anastrozole 1 mg/d, or exemestane 25 mg/d) for 36 months, followed by ET alone as SOC per investigator's clinical judgment. Pre/peri-menopausal women and men will receive goserelin 3.6 mg or leuprolide 3.75 mg/4 wk...Recruitment is ongoing. Clinical trial information: NCT05827081."

Clinical • P3 data • Breast Cancer • Heart Failure • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2

Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial. (ASCO 2025) - P3 | "Patients (pts) were randomized (1:1) to receive oral Dalp (125 mg QD; 3-wk on/1-wk off, for 2 y) + ET (letrozole 2.5 mg/anastrozole 1 mg/tamoxifen 10 mg/toremifene 60 mg QD, for 5 y) or placebo + ET. Addition of Dalp to ET as adjuvant treatment significantly improved iDFS, with a tolerable safety profile. These data support the use of Dalp for treating HR+/HER2- early BC. Efficacy outcomes.*Kaplan–Meier method."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - P2 | N=327 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: University of California, San Francisco | Active, not recruiting ➔ Completed | Phase classification: P1b ➔ P1

Phase classification • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Margin Width and Local Recurrence in the NRG Oncology/NSABP B-35 DCIS Lumpectomy Trial (ASBrS 2025) - P3 | "Local recurrence rates were similar in the tamoxifen and anastrozole arms of the trial providing an opportunity to analyze the effect of margin width on ipsilateral breast tumor recurrence (IBTR) and all breast cancer events. The differences in 10-year IBTR cumulative incidences between the 1mm and 2mm cutoffs for margin width (5.6% vs 5.3% for < 1mm vs < 2mm, respectively, and 4.0% vs 3.8% for ≥1mm vs ≥2mm, respectively) are clinically minimal. These results indicate that the need to undertake re-excision lumpectomies based on margin width among post-menopausal women receiving lumpectomy, breast irradiation, and adjuvant endocrine therapy should be reconsidered. NCT 00053898 Support: U10-80868, -180822, UG1CA189867."

Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) - P3 | N=250 | Active, not recruiting | Sponsor: Tolmar Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - P=N/A | N=42 | Completed | Sponsor: University of Maryland, Baltimore | Recruiting ➔ Completed | N=90 ➔ 42 | Trial completion date: Mar 2025 ➔ Aug 2024

Enrollment change • Trial completion • Trial completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Obesity • Oncology • Solid Tumor • ER • HER-2

Synthesis, Characterization, and In Vitro and In Silico Studies of New Triazole Derivatives as Aromatase Inhibitors. (PubMed, Med Chem) - "The interactions observed as a result of molecular docking and dynamics studies are in harmony with activity studies. In particular, interactions with HEM600 demonstrate the activity potential of the compound."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

Cannabinol improves exemestane efficacy in estrogen receptor-positive breast cancer models: a comparative study with cannabidiol. (PubMed, Eur J Pharmacol) - "In line with this, and following our previous work, the benefits of combining the aromatase inhibitors (AIs) used in the clinic, anastrozole (Ana), letrozole (Let), and exemestane (Exe), with cannabinol (CBN) were evaluated. By comparing these two therapeutic strategies, as well as the previously studied combination of Exe plus cannabidiol (CBD), differential transcriptome profiles were detected, which may help to better understand the mechanism of action of cannabinoids and disclose their full potential in breast cancer treatment. In conclusion, this study strengthens the hypothesis that cannabinoids are important anti-cancer agents with attractive co-adjuvant properties."

Journal • Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CYP19A1 • ER

ALISCA-Breast1: A phase II study of ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast CAncer (ESMO-BC 2025) - P2 | "Eligible patients are randomized 1:1:1 to alisertib 30, 40, or 50 mg orally bid on d1−3, 8–10, and 15–17 q28d, plus physician's choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not previously used in recurrent/metastatic setting or progressed upon in adjuvant setting; up to 50 patients will be randomized per arm in the USA and Europe. All biomarkers will be assessed centrally. The study will determine the optimal alisertib dose to combine with ET."

Clinical • Combination therapy • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2